Updates to an FDA-approved colorectal cancer blood test increased the detection of advanced precancerous lesions, a new study showed. “The updated test has improved performance, better detection of advanced precancerous lesions, resulting in larger projected reductions in CRC incidence and mortality at the population level,” said first author Aasma Shaukat, MD, MPH, of the NYU Grossman School of Medicine in New York City. Although colonoscopy and stool-based testing continue to be recommended as first-line screening in American Cancer Society guidelines, “for patients who are unwilling or just will not proceed with screening, we can consider offering them a blood test,” said Shaukat, who presented the findings at the American College of Gastroenterology 2026 Annual Scientific Meeting. Read more at the link: mdsc.pe/3U6r4CY